Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognostic value of PSMA-T4 imaging in triple-negative breast cancer undergoing radical therapy
2025-525110-29-01Phase 3Authorised
- Sponsor
- National Centre for Nuclear Research
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of PSMA-T4 in triple-negative breast cancer (TNBC), sponsored by National Centre for Nuclear Research. Primary endpoint: Primary endpoint: Post-operative histopathological PSMA expression. Planned start Aug 2026; status: authorised.
02
Drugs
PSMA-T4
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2025-525110-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525110-29-01.